
In Episode 2, Part 2, Cheryl Allen, Nick Calla and Rena Goins discuss where traditional channel models break down as therapies grow more complex.
Genentech, Genzyme and Vetter announce new capital investments
Last week was a good one for construction engineers tracking the biopharma industry. Three significant new capital investments were announced; notably, all three involve biologics, giving more evidence (in case anyone needed it) that the industry is shifting more and more into biotech products.






